Technetium Tc-99M Mertiatide Kit

Prostate‐specific membrane antigen (PSMA)‐targeted radioligand therapy (RLT) may be associated with renal toxicity. We aimed to identify predictive parameters for the development of chronic kidney disease (CKD) in patients with metastatic castration resistant prostate cancer (mCRPC) undergoing RLT.

In 46 mCRPC patients scheduled for Lu‐177‐PSMA‐RLT, pretherapeutic estimated glomerular filtration rate (eGFR [ml/min/1.73 m2]), Tc‐99m‐mercaptoacetyltriglycine (Tc‐99m‐MAG3) clearance and baseline Ga‐68‐PSMA‐ligand positron emission tomography (PET)‐derived renal cortical uptake and PSMA‐tumor volume (TV) were determined. We tested the predictive capability of these parameters and clinical risk factors for the occurrence of CKD (defined as CTCAE vers. 5.0 grade 2 or higher) during follow‐up.

After 4 ± 3 cycles of RLT average eGFR declined from 76 ± 17 to 72 ± 20 ml/min/1.73 m2(p = 0.003). Increased estimated renal radiation dose (eRRD) was significantly associated with renal functional decline (p = 0.008). During follow‐up, 16/46 (30.4%) developed CKD grade 2 (no grade 3 or higher). In receiver operating characteristic (ROC) analysis, pretherapeutic eGFR was highly accurate in identifying the occurrence of CKD vs no CKD with an area under the curve (AUC) of 0.945 (p < 0.001; best threshold, 77 ml/min/1.73 m2), followed by Tc‐99m‐MAG3‐derived tubular extraction rate (TER; AUC, 0.831,p < 0.001; best threshold, 200 ml/min/1.73 m2). Renal PET signal (p = 0.751) and PSMA‐TV (p = 0.942), however, were not predictive. Kaplan–Meier analyses revealed adverse renal outcome for patients with lower eGFR (p = 0.001) and lower scintigraphy‐derived TER (p = 0.009), with pretherapeutic eGFR emerging as the sole predictive parameter in multivariate analysis (p = 0.007).

Serious adverse renal events are not a frequent phenomenon after PSMA‐targeted RLT. However, in patients developing moderate CKD after RLT, pretherapeutic eGFR is an independent predictor for renal impairment during follow‐up.